GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Beneish M-Score

Amcad Biomed (ROCO:4188) Beneish M-Score : -1.83 (As of Dec. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.83 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Amcad Biomed's Beneish M-Score or its related term are showing as below:

ROCO:4188' s Beneish M-Score Range Over the Past 10 Years
Min: -3.63   Med: -1.63   Max: 59.13
Current: -1.83

During the past 13 years, the highest Beneish M-Score of Amcad Biomed was 59.13. The lowest was -3.63. And the median was -1.63.


Amcad Biomed Beneish M-Score Historical Data

The historical data trend for Amcad Biomed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Beneish M-Score Chart

Amcad Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.50 -2.75 -1.63 -2.84 -1.26

Amcad Biomed Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.03 -1.26 -2.66 -2.17 -1.83

Competitive Comparison of Amcad Biomed's Beneish M-Score

For the Medical Devices subindustry, Amcad Biomed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Beneish M-Score falls into.



Amcad Biomed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Amcad Biomed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.7232+0.528 * 0.9965+0.404 * 0.7152+0.892 * 1.0493+0.115 * 0.9641
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0059+4.679 * -0.008607-0.327 * 0.68
=-1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was NT$12.44 Mil.
Revenue was 10.517 + 16.37 + 8.078 + 23.414 = NT$58.38 Mil.
Gross Profit was 5.639 + 11.151 + 3.315 + 15.836 = NT$35.94 Mil.
Total Current Assets was NT$511.98 Mil.
Total Assets was NT$698.65 Mil.
Property, Plant and Equipment(Net PPE) was NT$83.71 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$18.59 Mil.
Selling, General, & Admin. Expense(SGA) was NT$53.74 Mil.
Total Current Liabilities was NT$24.10 Mil.
Long-Term Debt & Capital Lease Obligation was NT$6.95 Mil.
Net Income was -17.922 + -10.24 + -15.639 + -10.902 = NT$-54.70 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.00 Mil.
Cash Flow from Operations was -13.627 + -12.652 + -15.359 + -7.052 = NT$-48.69 Mil.
Total Receivables was NT$6.88 Mil.
Revenue was 15.705 + 15.612 + 10.525 + 13.793 = NT$55.64 Mil.
Gross Profit was 10.26 + 9.307 + 5.621 + 8.945 = NT$34.13 Mil.
Total Current Assets was NT$330.14 Mil.
Total Assets was NT$519.59 Mil.
Property, Plant and Equipment(Net PPE) was NT$82.39 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$17.50 Mil.
Selling, General, & Admin. Expense(SGA) was NT$50.92 Mil.
Total Current Liabilities was NT$22.87 Mil.
Long-Term Debt & Capital Lease Obligation was NT$11.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.444 / 58.379) / (6.882 / 55.635)
=0.213159 / 0.123699
=1.7232

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(34.133 / 55.635) / (35.941 / 58.379)
=0.613517 / 0.615649
=0.9965

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (511.984 + 83.709) / 698.649) / (1 - (330.141 + 82.39) / 519.586)
=0.147364 / 0.206039
=0.7152

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=58.379 / 55.635
=1.0493

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(17.496 / (17.496 + 82.39)) / (18.585 / (18.585 + 83.709))
=0.17516 / 0.181682
=0.9641

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(53.742 / 58.379) / (50.917 / 55.635)
=0.920571 / 0.915197
=1.0059

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.954 + 24.102) / 698.649) / ((11.095 + 22.87) / 519.586)
=0.044452 / 0.065369
=0.68

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-54.703 - 0 - -48.69) / 698.649
=-0.008607

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Amcad Biomed has a M-score of -1.83 suggests that the company is unlikely to be a manipulator.


Amcad Biomed Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Amcad Biomed Business Description

Traded in Other Exchanges
N/A
Address
No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from Europe. The company has two segments: Medical diagnostic software: which is responsible for the development and sales of smart medical imaging diagnostic software device and Precision medical equipment: which is responsible for research, development, manufacturing and sales of high-end ultrasonic probes.

Amcad Biomed Headlines

No Headlines